Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Blood (2009) 114 (22): 339.

https://doi.org/10.1182/blood.V114.22.339.339

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.

Blood (2009) 114 (22): 3281.

https://doi.org/10.1182/blood.V114.22.3281.3281

Published: 2009

Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Blood (2009) 114 (22): 862.

https://doi.org/10.1182/blood.V114.22.862.862

Published: 2009

Journal Articles

NDRG1 Expression Is Inhibited in AML and Its Knockdown Attenuates Neutrophil Differentiation.

Mario P. Tschan, PhD, Deborah Shan, Judith Laedrach, Marianne Eyholzer, Elisabeth Oppliger Leibundgut, PhD, Gabriela Baerlocher, MD, Andreas Tobler, MD, Deborah Stroka, PhD, Martin F. Fey, MD

Blood (2008) 112 (11): 927.

https://doi.org/10.1182/blood.V112.11.927.927

Published: 2008

Journal Articles

Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV

Blood (2008) 112 (11): 333.

https://doi.org/10.1182/blood.V112.11.333.333

Published: 2008

Journal Articles

Blocking the Autophagy Gene 5 (ATG5) Impairs ATRA-Induced Myeloid Differentiation, and ATG5 Is Downregulated in AML

Adrian Britschgi, MSc, Shida Yousefi, PhD, Judith Laedrach, Deborah Shan, Hans-Uwe Simon, MD, PhD, Andreas Tobler, MD, Martin F. Fey, MD, Mario P. Tschan, PhD

Blood (2008) 112 (11): 309.

https://doi.org/10.1182/blood.V112.11.309.309

Published: 2008

Journal Articles

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Blood (2008) 112 (11): 184.

https://doi.org/10.1182/blood.V112.11.184.184

Published: 2008

Journal Articles

The Anti-Apoptotic Gene BCL2A1 Is Transcriptionally Regulated by PU.1

Mathias Jenal, MSc, Venkateshwar A. Reddy, PhD, Judith Laedrach, Deborah Shan, Andreas Tobler, MD, Bruce E. Torbett, PhD, Martin F. Fey, MD, Mario P. Tschan, PhD

Blood (2008) 112 (11): 3579.

https://doi.org/10.1182/blood.V112.11.3579.3579

Published: 2008

Journal Articles

Green Tea Catechin Epigallocatechin-3-Gallate (EGCG) Induces Cell Death in Acute Myeloid Leukemic Cells Via DAPK2 and Potentiates ATRA-Induced Neutrophil Differentiation

Adrian Britschgi, MSc, Hans-Uwe Simon, MD, PhD, Andreas Tobler, MD, Martin F. Fey, MD, Mario P. Tschan, PhD

Blood (2008) 112 (11): 2628.

https://doi.org/10.1182/blood.V112.11.2628.2628

Published: 2008

Journal Articles

A Randomized Study of Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine in Patients with Hairy Cell Leukemia.

Reinhard Zenhausern, MD, Nicolas Leupin, Shu-Fang Hsu Schmitz, Max Solenthaler, Andre Tichelli, Dominik Heim, Urs Hess, Leda Leoncini, Mario Bargetzi, Andreas Tobler

Blood (2007) 110 (11): 1352.

https://doi.org/10.1182/blood.V110.11.1352.1352

Published: 2007

Journal Articles

Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia.

Wolfgang C. Korte, MD, Lukas Graf, MD, Andreas Tobler, MD

Blood (2007) 110 (11): 3771.

https://doi.org/10.1182/blood.V110.11.3771.3771

Published: 2007

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Ute Berger, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Claudia Schoch, MD, Andreas Reiter, MD, Gerhard Ehninger, MD, Thomas Fischer, MD, Alois Gratwohl, MD, Joerg Hasford, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Hans-J. Kolb, MD, Stefan Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Andreas Tobler, MD, Ruediger Hehlmann, MD, The German CML-Study Group

Blood (2005) 106 (11): 1083.

https://doi.org/10.1182/blood.V106.11.1083.1083

Published: 2005

Journal Articles

Enhancing Neutrophil Differentiation - A Novel Role for the Death-Associated Protein Kinase 2 (DAPK2).

Mattia Rizzi, MD, Christian Britschgi, MD, Mario P. Tschan, PhD, Tobias J. Grob, MD, PhD, Barbara Huegli, Nicolas Leupin, MD, Beatrice U. Mueller, MD, Andrew Ziemiecki, PhD, Bruce E. Torbett, PhD, Martin F. Fey, MD, Andreas Tobler, MD

Blood (2005) 106 (11): 1348.

https://doi.org/10.1182/blood.V106.11.1348.1348

Published: 2005

Journal Articles

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Guntram Buesche, Ruediger Hehlmann, Arnold Ganser, Hartmut Hecker, Mathias Freund, Hermann Heimpel, Barbara Heinze, Dorothea Gadzicki, Brigitte Schlegelberger, Christa Fonatsch, Bernd Frye, Andreas Tobler, Axel Georgii, Hans H. Kreipe

Blood (2005) 106 (11): 1106.

https://doi.org/10.1182/blood.V106.11.1106.1106

Published: 2005

Journal Articles

Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase.

Ute Berger, MD, Andreas Hochhaus, MD, Andreas Reiter, MD, Markus Pfirrmann, Claudia Schoch, MD, Gerhard Ehninger, MD, Thomas Fischer, MD, Alois Gratwohl, MD, Joerg Hasford, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Hans-J. Kolb, MD, Stefan Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Andreas Tobler, MD, Rüdiger Hehlmann, MD, the German CML-Study Group

Blood (2004) 104 (11): 24.

https://doi.org/10.1182/blood.V104.11.24.24

Published: 2004

Journal Articles

A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)

Urban Novak, Elisabeth Oppliger Leibundgut, Jörg Hager, Dominique Mühlematter, Martine Jotterand, Celine Besse, Nicolas Leupin, Daniel Ratschiller, Jeanette Papp, Gina Kearsey, Stefan Aebi, Hans Graber, Rolf Jaggi, Jean-Marc Lüthi, Sandrine Meyer-Monard, Mark Lathrop, Andreas Tobler, Martin F. Fey

Blood (2002) 100 (5): 1787–1794.

https://doi.org/10.1182/blood.V100.5.1787.h81702001787_1787_1794

Published: 2002

Journal Articles

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Blood (1999) 94 (11): 3668–3677.

https://doi.org/10.1182/blood.V94.11.3668

Published: 1999

NARROW

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

NDRG1 Expression Is Inhibited in AML and Its Knockdown Attenuates Neutrophil Differentiation.

Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV

Blocking the Autophagy Gene 5 (ATG5) Impairs ATRA-Induced Myeloid Differentiation, and ATG5 Is Downregulated in AML

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

The Anti-Apoptotic Gene BCL2A1 Is Transcriptionally Regulated by PU.1

Green Tea Catechin Epigallocatechin-3-Gallate (EGCG) Induces Cell Death in Acute Myeloid Leukemic Cells Via DAPK2 and Potentiates ATRA-Induced Neutrophil Differentiation

A Randomized Study of Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine in Patients with Hairy Cell Leukemia.

Erythropoietin Supplementation in Patients with Refractory Anemia and Mild Renal Insufficiency - MDS Meets Renal Anemia.

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.

Enhancing Neutrophil Differentiation - A Novel Role for the Death-Associated Protein Kinase 2 (DAPK2).

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase.

A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only